Product
Universal CD19 CAR-T
1 clinical trial
5 indications
Indication
Neuromyelitis Optica Spectrum DisordersIndication
Myasthenia GravisIndication
GeneralizedIndication
Multiple SclerosisClinical trial
An Exploratory Study on the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases of the Nervous SystemStatus: Not yet recruiting, Estimated PCD: 2026-12-31